Has Roberto Osorio Manotas, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,050 in general payments to Roberto Osorio Manotas, MD across 60 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roberto Osorio Manotas, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roberto Osorio Manotas, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roberto Osorio Manotas, MD

Gastroenterology · Bayamon, PRNPI 1215123161

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,970 of the $3,050 with a category attached, or 64.6%. 9 manufacturers reported payments, led by Olympus Corporation Of The Americas at 37.6% of the total. Reporting peaked in 2019 at $1,050 and has fallen 53.7% since, to $486 in 2025.

$3,050in general payments, 2019–2025

Across 60 payments — averaging $50.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Olympus Corporation Of The Americas$1K
AbbVie$888
E.r. Squibb & Sons, L.L.C.$308
Boston Scientific$177
Omniscient Neurotechnology America Ltd$164
Madrigal Pharmaceuticals$144
plus $223 from 3 others

$22,094in research payments, 2019–2025

Across 7 payments — averaging $3156.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$22K

What the payments were for

Travel & lodging$1,08035%
Food & beverage$1,97065%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Olympus Corporation Of The Americas	7	$1,146
AbbVie	34	$888
E.r. Squibb & Sons, L.L.C.	5	$308
Boston Scientific	2	$177
Omniscient Neurotechnology America Ltd	1	$164
Madrigal Pharmaceuticals	1	$144
PBG Puerto Rico LLC	5	$95
Eli Lilly Export S.A. Puerto Rico Branch	3	$86
Johnson & Johnson	2	$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,050 in reported general payments places this provider in the 65th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$12,583

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	27	$184,511
SuprepSodium, Potassium,mag Sulfates	277	$32,589
SutabSod Sulf/Pot Chloride/Mag Sulf	192	$31,632
LinzessLinaclotide	46	$24,956
Sucralfate	33	$2,861
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	35	$2,568
Esomeprazole Magnesium	103	$2,352
Omeprazole	310	$2,181
Clarithromycin	35	$1,252
Midazolam HclMidazolam Hcl/Pf	410	$1,091
CholestyramineCholestyramine (With Sugar)	14	$969
Pantoprazole Sodium	111	$861
Amoxicillin	35	$638
Metronidazole	40	$559
Fentanyl CitrateFentanyl Citrate/Pf	143	$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieLinzess	$888	$24,95646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in Bayamon

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →